Form 13G PULMONX CORPORATION For: 9 March
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pulmonx Corp (LUNG)
Pulmonx Corp stock price live, this page displays NASDAQ LUNG stock exchange data. View the LUNG premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pulmonx Corp real time stock price chart below.
What Is the Pulmonx Corp Stock Price Today?
The Pulmonx Corp stock price today is 1.51.
What Is the Stock Symbol for Pulmonx Corp?
The stock symbol for Pulmonx Corp is "LUNG."
What Stock Exchange Does Pulmonx Corp Trade On?
Pulmonx Corp is listed and trades on the NASDAQ stock exchange.
Is Pulmonx Corp a Good Stock to Buy?
Determining whether Pulmonx Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LUNG quote. (ISIN: US7458481014)
What Is the Pulmonx Corp Stock Price Today?
The Pulmonx Corp stock price today is 1.51.
What Is the Stock Symbol for Pulmonx Corp?
The stock symbol for Pulmonx Corp is "LUNG."
What Stock Exchange Does Pulmonx Corp Trade On?
Pulmonx Corp is listed and trades on the NASDAQ stock exchange.
Is Pulmonx Corp a Good Stock to Buy?
Determining whether Pulmonx Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LUNG quote. (ISIN: US7458481014)
1.51
+0.04(+2.38%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.46
1.52
52 wk Range
1.13
5.46
Earnings results expected in 9 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.461.52
52 wk Range
1.135.46
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LUNG Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
5.17
Upside
+242.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Pulmonx Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 13G PULMONX CORPORATION For: 9 March
- Investing.com
- Pulmonx Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Pulmonx Corp Earnings Call Summary for Q4/2025
- Q4 2025 EPS of -$0.25 beat estimates by 35.9%, but revenue of $22.59M missed forecasts by 2.67%; stock fell 5.88% to $1.53
- International revenue surged 23% YoY, offsetting an 11% U.S. market decline; gross margin improved to 77.6% from 74%
- Strategic restructuring underway with sales force adjustments; operating expenses expected to decline 7-9% in 2026
- AeriSeal program prioritized to expand addressable market by 20% globally; focus on international expansion continues
- Net loss narrowed to $10.4M from $13.2M YoY; company maintains strong liquidity with more cash than debt on balance sheet
Last Updated: 2026-03-04, 05:38 p/m
Read Full TranscriptCompare LUNG to Peers and Sector
Metrics to compare | LUNG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLUNGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −3.6x | −0.5x | |
PEG Ratio | −0.14 | 0.05 | 0.00 | |
Price/Book | 1.2x | 3.1x | 2.6x | |
Price / LTM Sales | 0.7x | 3.4x | 3.2x | |
Upside (Analyst Target) | 138.1% | 50.1% | 44.2% | |
Fair Value Upside | Unlock | 17.9% | 5.5% | Unlock |
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.17
(+242.16% Upside)
Earnings
Latest Release
Mar 04, 2026
EPS / Forecast
-0.25 / -0.39
Revenue / Forecast
22.59M / 23.21M
People Also Watch
FAQ
What Is the Pulmonx (LUNG) Stock Price Today?
The Pulmonx stock price today is 1.51 USD.
What Stock Exchange Does Pulmonx Trade On?
Pulmonx is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Pulmonx?
The stock symbol for Pulmonx is "LUNG."
What Is the Pulmonx Market Cap?
As of today, Pulmonx market cap is 63.78M USD.
What Is Pulmonx's Earnings Per Share (TTM)?
The Pulmonx EPS (TTM) is -1.33.
When Is the Next Pulmonx Earnings Date?
Pulmonx will release its next earnings report on Apr 29, 2026.
From a Technical Analysis Perspective, Is LUNG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Pulmonx Stock Split?
Pulmonx has split 0 times.
How Many Employees Does Pulmonx Have?
Pulmonx has 296 employees.
What is the current trading status of Pulmonx (LUNG)?
As of Apr 20, 2026, Pulmonx (LUNG) is trading at a price of 1.51 USD, with a previous close of 1.47 USD. The stock has fluctuated within a day range of 1.46 USD to 1.52 USD, while its 52-week range spans from 1.13 USD to 5.46 USD.
What Is Pulmonx (LUNG) Price Target According to Analysts?
The average 12-month price target for Pulmonx is 5.17 USD, with a high estimate of 14 USD and a low estimate of 2.5 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +242.16% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.